In a 2025 randomized controlled trial published in JAMA Psychiatry , semaglutide significantly reduced weekly alcohol cravings compared with placebo, although reductions in overall alcohol consumption were less consistent
They reported less weekly craving and during the test at the end, they drank less and had lower breath alcohol than they had during the initial session
Danuglipron: Developed by Pfizer and intended to keep blood glucose at healthy levels, this oral GLP-1 recently completed Phase 2 clinical trials for the treatment of type 2 diabetes and obesity
This delay contrasts with tirzepatide, which is currently accessible in the United States and has recently obtained approval in Europe.217 Adverse Reactions and Safety of GLP-1RAs and GLP-1/GIP Dual Receptor Agonist GLP-1RAs and dual agonists targeting GLP-1 and GIP receptors have demonstrated considerable efficacy in the treatment of T2DM and obesity
The opposing effects of GIP and GLP-1 on lipogenesis and lipolysis, respectively, help maintain adipocytes in young and healthy state, fostering higher levels of adiponectin a key adipokine known for its potential antidiabetic, anti-inflammatory, and antiatherogenic properties (185)
)
